Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

9861
9956
PBORR
80574
syndrome. Postgrad Ob Gyn 1995;15:1-5
Luxol Fast Blue/Cresyl Violet (LFB/CV) Stain for Myelin and
Nerve Cells
Useful For: "Overview" stain for central and peripheral nerve tissues, particularly for evidence of
demyelination.
Reference Values:
The laboratory will provide a pathology consultation and stained slide.
Luxol Fast Blue/Periodic Acid-Schiff Stain for Myelin and Its
Breakdown Products
Useful For: Method for myelin breakdown and its breakdown products (in phagocytes) and blood
vessels.
Reference Values:
The laboratory will provide a pathology consultation and stained slide.
Lyme Disease (Borrelia burgdorferi), Molecular Detection, PCR
Clinical Information: Lyme disease is a multisystem and multistage infection caused primarily by 3
species of tick-borne spirochetes in the Borrelia burgdorferi sensu lato genogroup. These spirochetes
include Borrelia burgdorferi sensu stricto (North America and Western Europe), Borrelia afzelii (Central
and Western Europe and Russia), and Borrelia garinii (Europe, Russia, and northern Asia). Endemic areas
for Lyme disease in the United States correspond with the distribution of 2 tick species, Ixodes scapularis
(Northeastern and Upper Midwestern US) and Ixodes pacificus (West Coast US). In Europe, Ixodes
ricinus transmits the spirochete. Lyme disease is the most commonly reported tick-borne infection in
Europe and North America (CDC). Lyme disease exhibits a variety of symptoms that may be confused
with immune and inflammatory disorders. Inflammation around the tick bite causes skin lesions.
Erythema (chronicum) migrans (ECM), a unique expanding skin lesion with central clearing that has a
ring-like appearance, is typically the first stage of the disease. Arthritis, neurological disease, and cardiac
disease may be later stage manifestations. Serology is currently the diagnostic method of choice for Lyme
disease. However, serology may not be positive until 2 to 4 weeks after onset of ECM, and direct
detection of Borrelia species. Target DNA using PCR may be a useful adjunct to existing diagnostic tests
for acute disease. PCR has shown utility for detection of Borrelia DNA from skin biopsies of ECM
lesions, as well as DNA from synovial and cerebrospinal fluid in late-stage disease.(1) Borrelia DNA can
also, rarely, be detected from blood, but is not the test of choice from this source. Lyme PCR may be
useful for adjunctive testing to support a serologic diagnosis of Lyme disease, and should be performed in
conjunction with FDA-approved serologic tests. PCR results should be correlated with serologic and
epidemiologic data and clinical presentation of the patient.
Useful For: Confirmation of active Lyme disease Supporting the diagnosis of Lyme arthritis Testing of
cerebrospinal fluid (CSF) by PCR in patients with suspected Lyme neuroborreliosis should be requested
only on patients with positive Borrelia burgdorferi antibody in serum confirmed by Western blot assay
LYWB/9535 Lyme Disease Antibody, Western Blot, Serum and with abnormal CSF findings (elevated
protein and WBC >10 cells/high-power field).
Interpretation: A positive result indicates the presence of DNA from Borrelia burgdorferi, the agent
of Lyme disease. A negative result indicates the absence of detectable DNA from Borrelia burgdorferi in
the specimen. Due to the clinical sensitivity limitations of the PCR assay, a negative result does not
preclude the presence of the organism or active Lyme disease.
Reference Values:
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1132